https://ly2606368inhibitor.com..../discovery-as-well-a
We report the initial clinical efficacy and protection effects of a new thin-strut cobalt chromium biolimus-eluting stent (CoCr-BES) from a worldwide multi-centre registry. Methods We learned 400 all-comer customers with coronary disease receiving CoCr-BES at 12 centers, with follow-up at 9 months and 2 many years. The principal endpoint had been occurrence of major unpleasant cardiac events (MACE) at 9 months comprising cardiac death, myocardial
Like
Comment
Share
